J.P. Kan - Concepedia

Author

J.P. Kan

Centre National de la Recherche Scientifique

Also Known As

J P Kan, J. P Kan, J. P. KAN, J. P. Kan, J.P. Kan, J.‐P. KAN, Jacob Kan, Jean Paul Kan, Jiahui Kan

Publications

434

Citations

H-Index

Concepts

All Affiliations

Centre National de la Recherche Scientifique Inserm

About

J.P. Kan is an author at Centre National de la Recherche Scientifique specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	373
2	Social Sciences	5	5	226
3	Biochemistry	5	5	179
4	Natural Sciences	2	2	41
5	Neurology	1	1	18

J.P. Kan

Publications

425

Citations

H-Index

Page 1

	Year	Citations
3-Aminopyridazine derivatives with atypical antidepressant, serotonergic and dopaminergic activities Camille G. Wermuth, Gilbert Schlewer, Jean Bourguignon, Journal of Medicinal Chemistry Psychoactive DrugPsychiatryBiochemistryMedicineSerotonergic Activities	1989	90
Daily variations of various parameters of serotonin metabolism in the rat brain. I. Circadian variations of tryptophan-5-hydroxylase in the raphe nuclei and the striatum J.P. Kan, Guy Chouvet, F. Héry, Brain Research Daily VariationsSerotonin MetabolismNeurophysiologyNeuroanatomyI. Circadian Variations	1977	64
Daily variations of various parameters of serotonin metabolism in the rat brain. II. Circadian variations in serum and cerebral tryptophan levels: Lack of correlation with 5-HT turnover F. Héry, Guy Chouvet, J.P. Kan, Brain Research Daily VariationsSerotonin MetabolismNeurophysiologyMedicinePhysiology	1977	64
Minaprine, a new drug with antidepressant properties. Kathleen Bizière, P. Worms, J.P. Kan, PubMed Vitro MinaprinePsychotropic MedicationPsychopharmacologyPharmacotherapySocial Sciences	1985	48
Characteristics of the Inhibition of Rat Brain Monoamine Oxidase <i>In Vitro</i> by MD780515 J.P. Kan, M. Strolin Benedetti Journal of Neurochemistry PharmacotherapyExperimental PharmacologySocial SciencesMolecular PharmacologyMedicinal Chemistry	1981	32
SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents. P. Worms, J.P. Kan, Camille G. Wermuth, Journal of Pharmacology and Experimental Therapeutics	1987	30
Monoamine oxidase inhibitory properties of 5-hydroxymethyl-3-<i>m</i>-tolyloxazolidin-2-one (toloxatone) J.P. Kan, Arthur Malone, M. Strolin Benedetti Journal of Pharmacy and Pharmacology Pharmaceutical SciencePharmacotherapyPharmaceutical ChemistryTranslational PharmacologyMolecular Pharmacology	1978	25
SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. J.P. Kan, R. Steinberg, Claire Mouget-Goniot, Journal of Pharmacology and Experimental Therapeutics	1987	22
Monoamine oxidase inhibition and brain amine metabolism after oral treatment with toloxatone in the rat P.E. Keane, J.P. Kan, Nicole Sontag, Journal of Pharmacy and Pharmacology Whole BrainPsychopharmacologyPharmacotherapySocial SciencesMolecular Pharmacology	1979	18
Pharmacological characterization of the aminopyridazine SR 95639A, a selective M1 muscarinic agonist Cees A. Schumacher, R. Steinberg, J.P. Kan, European Journal of Pharmacology Molecular PharmacologyPharmacological CharacterizationBiochemistryAminopyridazine Sr 95639AMedicine	1989	16

Page 1